Research Article
Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study
Table 3
Pregnancy outcomes in cases and controls.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data shown as median [IQR] or (%); †patients with available data (for remainder of study population not reported/unknown). ‡Minor maternal outcomes: malaise (2 in case group), abdominal pain (3 in case group, 2 in control group), nausea and vomiting of pregnancy (NVP) (3 in case group, 3 in control group), premature contractions (3 in case group), Preterm Premature Rupture Of Membranes (PPROM) (4 in case group, 5 in control group), impaired renal function (1 in case group), meconium amniotic (1 in case group), vaginal blood loss (1 in case group, 1 in control group), preeclampsia (3 in case group), hypertension (2 in case group, 3 in control group), severe hypertension (1 in case group), postpartum hypertension (1 in control group), fever (2 in case group), postpartum fever (2 in control group), urinary tract infection (2 in case group), trauma (1 in case group), reduced signs of fetal life (2 in case group), back pain (1 in case group), tachycardia (1 in case group), gestational diabetes (2 in case group, 1 in control group), herpes gestationis (1 in case group), gestational pyelitis (1 in control group), pulmonary embolism (1 in control group), and positive discongruence (1 in control group). Hb: hemoglobin; IQR: interquartile range; ICU: intensive care unit; IUGR: intrauterine growth retardation. |